Is Tranylcypromine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Tranylcypromine.

Is Tranylcypromine approved by the US FDA?

Drugs@FDA lists 4 application product lines for Tranylcypromine, including PARNATE (Prescription); TRANYLCYPROMINE SULFATE (Prescription); TRANYLCYPROMINE SULFATE (Prescription); TRANYLCYPROMINE SULFATE (Prescription).

Are there safety signals or safety updates for Tranylcypromine?

US FDA: 1 entry (latest 2018-01-04).

Active substance

Tranylcypromine

SFDA 1
US FDA 4
Health Canada 2
US price lines 1
NHS prices 1
Safety 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
PARNATE 10 MG. TAB.	10 mg	Tablet · Oral use	50 Blister	SAR 16.85	NCE · Prescription	SMIITHKLINE BEECHAM	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
PARNATE	EQ 10MG BASE	tablet · oral	ADVANZ PHARMA	Prescription	21 Feb 1961
TRANYLCYPROMINE SULFATE	EQ 10MG BASE	tablet · oral	STRIDES PHARMA INTL	Prescription	29 Jun 2006
TRANYLCYPROMINE SULFATE	EQ 10MG BASE	tablet · oral	NOVITIUM PHARMA	Prescription	17 Apr 2018
TRANYLCYPROMINE SULFATE	EQ 10MG BASE	tablet · oral	CROSSMEDIKA SA	Prescription	27 Jun 2022

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
M-TRANYLCYPROMINE	02542188	10 MG	TABLET · ORAL	MANTRA PHARMA INC
PARNATE	01919598	10 MG	TABLET · ORAL	GLAXOSMITHKLINE INC

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	TRANYLCYPROMINE SULF 10 MG TAB	$0.5911	per EA	23 Sep 2026
NHS Drug Tariff	Tranylcypromine 10mg tablets	£485.00	28 tablet	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

US FDA 4 Jan 2018 PARNATE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for tranylcypromine →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.